



US006605286B2

(12) **United States Patent**
Steidler et al.

(10) **Patent No.:** **US 6,605,286 B2**
(45) **Date of Patent:** **Aug. 12, 2003**

(54) **DELIVERY OF BIOLOGICALLY ACTIVE POLYPEPTIDES**

(75) Inventors: **Lothar Steidler**, Ghent (BE); **Erik Remaut**, Ghent (BE); **Jeremy Mark Wells**, Cambridge (GB); **Richard William Falla Le Page**, Cambridge (GB)

(73) Assignees: **Vlaams Interuniversitair Instituut voor Biotechnologie**, Zwijnaarde (BE); **Microbial Technics Limited**, Cambridge (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/060,878**

(22) Filed: **Apr. 16, 1998**

(65) **Prior Publication Data**

US 2001/0006642 A1 Jul. 5, 2001

Related U.S. Application Data

(63) Continuation of application No. PCT/GB96/02580, filed on Oct. 21, 1996.

(30) **Foreign Application Priority Data**

Oct. 20, 1995 (GB) 9521568

(51) **Int. Cl.**⁷ **A61K 39/00**; A61K 39/12; A61K 39/085; A61K 38/00; A01N 37/18

(52) **U.S. Cl.** **424/243.1**; 424/184.1; 424/192.1; 424/200.1; 424/258.1; 424/199.1; 424/198.1; 435/252.3; 435/320.1; 514/2; 514/3

(58) **Field of Search** 424/184.1, 243.1, 424/192.1, 200.1, 258.1, 198.1, 199.1; 435/252.3, 320.1; 514/2, 3

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,032,510 A	*	7/1991	Kovacevic et al.	435/69.1
5,149,532 A	*	9/1992	Brunell	424/89
5,240,705 A	*	8/1993	Jacobs	424/164.1
5,330,753 A	*	7/1994	Mekalanos et al.	424/190.1
5,364,774 A	*	11/1994	Muir et al.	
5,401,642 A	*	3/1995	Fiers et al.	
5,401,658 A	*	3/1995	Fiers et al.	
5,417,986 A	*	5/1995	Reid et al.	424/422
5,455,034 A	*	10/1995	Nagaraja et al.	424/130.1
5,504,005 A	*	4/1996	Bloom et al.	435/253.1
5,547,664 A	*	8/1996	Charles et al.	424/93.2
5,559,007 A	*	9/1996	Suri et al.	435/69.1
5,591,632 A	*	1/1997	O'Donnell et al.	435/252.3
5,733,540 A	*	3/1998	Lee	
5,824,538 A	*	10/1998	Branstrom et al.	
6,100,388 A	*	8/2000	Casas et al.	536/23.1
6,130,082 A	*	10/2000	Majarjan et al.	424/192.1
6,190,662 B1	*	2/2001	Steidler et al.	424/184.1
6,190,669 B1	*	2/2001	Noriega et al.	424/258.1
6,221,648 B1	*	4/2001	Le Page et al.	435/252.3
6,261,561 B1	*	7/2001	Stewart et al.	424/184.1

FOREIGN PATENT DOCUMENTS

EP	0 176 320	*	4/1986
EP	0 449 770 A2	*	10/1991
GB	2278358 A		11/1994
GB	2278358	*	11/1994
WO	WO 90/00594	*	1/1990
WO	WO 91/06654	*	5/1991
WO	WO 93/17117	*	9/1993
WO	WO 95/03418	*	2/1995
WO	WO 96/11277	*	4/1996

OTHER PUBLICATIONS

Bojovic et al *Applied and Environ. Microbiol.* 57/2: 385-388, 1991.*

Steidler et al, *J. Bacteriol.* 175/23: 7639-7643, 1993.*

Norton et al, *FEMS Microbiol Letters* 120: 249-256, 1994.*

Wells et al, *Molecular Microbiol.* 8/6: 1155-1162, 1993.*

Wells et al, *Applied and Environ. Microbiol.* 59/11: 3954-3959, 1993.*

Wells et al, *Int. Dairy Journal*, 5: 1071-1079, 1995.*

Edwards et al, *Infection and Immunity* 60/6: 2514-2521, 1992.*

Iwaki et al, *Infection Immunity* 58/9: 2929-2934, 1990.*

Brett et al. *Eur. J. Immunol.* 23: 1608-1614, 1993.*

Sibakov et al, *Applied and Environ. Microbiol* 57/2: 341-348, 1991.*

Robinson et al, *Nature Biotechnology* 15:653-57, 1997.*

Steidler et al. *Infection and Immunity* 66/7:3183-3189, 1998.*

Holmes et al, *Infection and Immunity* 66/10: 4633-4639, 1998.*

Norton et al, *Vaccine*, 15/6-7: 616-619, 1997.*

Norton et al, *FEMS Immunol. and Medical Microbiol.* 14:167-177, 1996.*

Steidler et al, *NATO ASI Series vol. H98* pp 63-79, 1996.*

Wells et al, *Antonie van Leeuwenhoek* 70:317-330, 1996.*

Heath et al., *Vaccine*, 7: 427-434 (1992).

Rapoport, *Current Opinion in Biotechnology*, 1: 21-27 (1990).

Boersma et al., (1995) "Lactobacillus as vectors with intrinsic adjuvanticity for safe live mucosal vaccines", *Biochemistry Supplement* 19A, p. 255.*

Gasson, (1990) "In vivo genetic systems in lactic acid bacteria", *FEMS Microbiol. Rev.* 87:43-60.*

(List continued on next page.)

Primary Examiner—Nita Minnifield
(74) *Attorney, Agent, or Firm*—TraskBritt

(57) **ABSTRACT**

Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.

30 Claims, 4 Drawing Sheets